Issues of spectrum and local sensitivity of E. coli in female patients with acute uncomplicated lower urinary tract infection – a review of M. Seitz study and own observations
DOI: https://dx.doi.org/10.18565/urology.2018.3.58-62
L.G. Spivak, L.M. Rapoport, D.V. Platonova, D.G. Tsarichenko, M.S. Evdokimov, Yu.L. Demidko, D.V. Enikeev, A.N. Rossolovsky
Department of Urology, Medical Faculty, I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University), Moscow, Russia; LLC «Family Polyclinic 4», Moscow, Russia; Research Institute of Uronephrology and Human Reproductive Health; Saratov state medical University. V. I. Razumovsky Ministry of health of Russia, Saratov, Russia
Relevance. Acute uncomplicated lower urinary tract infections (AULUTI) are one of the most common diseases in urological practice. The management of cystitis is commonly based on antibacterial therapy. Despite the high efficiency, inadequate prescription of antibiotics leads to an increase in microorganisms’ resistance. In light of these matters, the selection of antibacterial agents to which the sensitivity of bacteria is the highest is becoming increasingly challenging.
Aim. To estimate the spectrum and local sensitivity of E. coli in patients with AULUTI.
Materials and methods. The present study analyzed the results of bacterial culture sampled from 45 patients with AULUTI. The mean age of the patients was 44±17 years. All bacterial cultures were obtained in out-patient settings in the framework of a multicenter initiative study on the prevention of recurrent AULUTI with d-mannose.
Results. Microbiological studies of the urine of patients with AULUTI revealed the growth of E. coli in concentrations ranging from 104 to 107 CFU/ml. Assessment of sensitivity demonstrated 100% sensitivity of Escherichia coli to fosfomycin trometamol.
Conclusion. According to the findings of microbiological studies, the patients with the AULUTI retain the highest sensitivity level of E.coli to phosphomycin trometamol, which allows it to be used as a first-line drug.
About the Autors
Corresponding author: L. G. Spivak –Associate Professor at the Department of Urology, I.M. Sechenov First MSMU of Minzdrav
of Russia (Sechenov University), Moscow, Russia; e-mail: leonid.spivak@gmail.com
Similar Articles